← Eichor
Condition: Advanced Or Metastatic Melanoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Or Metastatic Melanoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627698A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembroliz
Phase 1/Phase 2 · 9 location(s) · ImmVira Pharma Co. Ltd · NCT04370587Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Phase 2 · 1 location(s) · Sheba Medical Center · NCT05909618A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiat
Phase 1 · 2 location(s) · Memorial Sloan Kettering Cancer Center · NCT05607095A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Phase N/A · 59 location(s) · Pierre Fabre Pharma GmbH · NCT04045691Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advance
Phase 1/Phase 2 · 4 location(s) · CJ Bioscience, Inc. · NCT05877430Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on C
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT05629546Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Phase 2 · 10 location(s) · Hanmi Pharmaceutical Company Limited · NCT07449754Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06295159Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma
NA · 5 location(s) · Azienda Ospedaliera di Perugia · NCT07050940Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab fo
Phase 1 · 1 location(s) · LG Chem · NCT06332755A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melan
Phase 3 · 110 location(s) · Regeneron Pharmaceuticals · NCT06246916Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Phase 2 · 37 location(s) · DualityBio Inc. · NCT06953089Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untrea
Phase 3 · 81 location(s) · Iovance Biotherapeutics, Inc. · NCT05727904A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · GeneMedicine Co., Ltd. · NCT06265025MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Phase 1/Phase 2 · 13 location(s) · Perspective Therapeutics · NCT05655312Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · AstraZeneca · NCT07115043Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Yale University · NCT07027488A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional
Phase 1/Phase 2 · 11 location(s) · GI Innovation, Inc. · NCT05824975A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Pliant Therapeutics, Inc. · NCT06270706
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.